<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480814</url>
  </required_header>
  <id_info>
    <org_study_id>CBS-PIK3CA</org_study_id>
    <nct_id>NCT04480814</nct_id>
  </id_info>
  <brief_title>A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue Samples of Patients With Metastatic ER+/HER2- Breast Cancer</brief_title>
  <official_title>A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue Samples of Patients With Metastatic ER+/HER2- Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmassist Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmassist Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conventional biopsy and surgical tumor resection are invasive procedures that capture only
      one instance of the progression of the tumor. However, the genome of tumor is not static, but
      it is constantly altered during treatment.

      Liquid biopsy is a non-invasive approach based on the extraction of information through
      peripheral blood analysis. It makes it possible to characterize the development of a solid
      tumor in real time, through detailed molecular analysis of circulating genetic material in
      peripheral blood.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">October 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance of PIK3CA kit in CTCs, plasma and tumor tissue samples of metastatic breast cancer patients</measure>
    <time_frame>18 months</time_frame>
    <description>The performance of PIK3CA kit on detecting mutations in CTCs samples of metastatic breast cancer patients will be assessed via Sensitivity, Specificity, Positive and Negative Predictive Values, Positive and Negative Likelihood Ratios, Accuracy and Diagnostic Odds Ratio. The point of primary evaluation in CTCs samples will be at baseline and droplet digital PCR will be used as reference method.
The performance of PIK3CA kit on detecting mutations in plasma-ctDNA, and tumor tissue samples of metastatic breast cancer patients will be assessed via Sensitivity, Specificity Positive and Negative Predictive Values, Positive and Negative Likelihood Ratios, Accuracy and Diagnostic Odds Ratio. The point of primary evaluation in plasma-ctDNA and tumor tissue samples will be at baseline and therascreen PIK3CA RGQ PCR Kit will be used as reference method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- To study the PIK3CA Mutation Status before and after treatment of metastatic breast cancer patients using PIK3CA kit.</measure>
    <time_frame>24 months</time_frame>
    <description>Presence of PIK3CA mutations at a second visit following to baseline of metastatic breast cancer patients using the PIK3CA kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- To assess the PIK3CA Mutation Status before treatment vs treatment response of metastatic breast cancer patients using PIK3CA kit.</measure>
    <time_frame>24 months</time_frame>
    <description>Association of PIK3CA mutations presence at baseline with clinical response to treatment (CR, PR, SD, PD) of metastatic breast cancer patients using PIK3CA kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- To correlate patients' survival status with PIK3CA mutations at baseline</measure>
    <time_frame>24 months</time_frame>
    <description>Metastatic breast cancer patients' survival status by presence of PIK3CA mutations at baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To study CK-19 expression in CTC samples</measure>
    <time_frame>24 months</time_frame>
    <description>Detection of CK-19 expression in CTCs</description>
  </other_outcome>
  <other_outcome>
    <measure>To study methylation status of ESR1 in CTC, ctDNA and tumor tissue samples</measure>
    <time_frame>24 months</time_frame>
    <description>Methylation status of ESR1 in CTC, plasma and tumor samples</description>
  </other_outcome>
  <other_outcome>
    <measure>To study the presence of other biomarkers in tissue and liquid biopsy sample (at baseline).</measure>
    <time_frame>24 months</time_frame>
    <description>Molecular profile of cancer biomarkers between tissue and peripheral blood samples</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic Breast Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PIK3CA kit</intervention_name>
    <description>Prospective investigation of clinical samples for evaluation of IVD clinical performance</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Metastatic Breast Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        120 with metastatic breast cancer 30 healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female aged â‰¥ 18 years of age.

          2. Histological confirmed ER+/HER2- metastatic Breast Cancer prior to beginning a
             treatment

          3. Life expectancy permits participation to the study.

          4. Available tumor tissue sample for molecular analysis.

          5. Signed informed consent form.

        Exclusion Criteria:

          1. Female younger than 18 years old.

          2. History of another malignancy within 3 years or current 2nd primary malignancy.

          3. Patients that have not signed the informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aretaieio University Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>21 0728 6000</phone>
      <email>info@aretaeio.com</email>
    </contact>
    <investigator>
      <last_name>Christos Papadimitriou, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens Attikon</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>0030 210 5831000</phone>
      <email>secrmeddir@attikonhospital.gr</email>
    </contact>
    <investigator>
      <last_name>Amanda Psyrri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupoli</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>25513 51000</phone>
      <email>nfopgna@pgna.gr</email>
    </contact>
    <investigator>
      <last_name>Stylianos Kakolyris, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolital Hospital</name>
      <address>
        <city>Piraeus</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>210 48 09 000</phone>
      <email>information@metropolitan-hospital.gr</email>
    </contact>
    <investigator>
      <last_name>Helena Linardou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liquid biopsy</keyword>
  <keyword>CTC</keyword>
  <keyword>Plasma</keyword>
  <keyword>PIK3CA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

